HUMA
Humacyte, Inc.
There isn't enough reported data to score HUMA yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
HUMA Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Under pressure | |
| Unavailable |
HUMA's profitability and cash flow are currently under pressure. There isn't enough data to rate its revenue and balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
HUMA PE Valuation
HUMA has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
HUMA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect HUMA's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
HUMA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.50 | -$0.27 |
| Q2 2026 | -$0.55 | -$0.10 |
| Q1 2026 | -$0.63 | +$0.06 |
| Q4 2025 | -$0.26 | +$1.00 |
| Q3 2025 | -$0.23 | +$1.11 |
| Q2 2025 | -$0.45 | +$0.81 |
| Q1 2025 | -$0.69 | +$0.31 |
| Q4 2024 | -$1.26 | -$0.19 |
HUMA is still losing money, but far less than before: $0.50 per share over the past year, against $1.34 at its worst in late 2024.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.83 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over HUMA on earnings quality, reporting a profit while its opponent remains loss making.
HUMA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1M | +37% |
| Q2 2026 | $406K | +35% |
| Q1 2026 | $495K | -4.3% |
HUMA's revenue is growing: $1M last quarter, up 37% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -2288% | +951 points |
| Q2 2026 | -6649% | +3227 points |
| Q1 2026 | -5845% | -1361 points |
| Q4 2025 | -6603% | N/A |
| Q3 2025 | -3239% | N/A |
| Q2 2025 | -9876% | N/A |
| Q1 2025 | -4484% | N/A |
| Q4 2020 | -12639% | N/A |
HUMA's operating margin was −2288% last quarter, up 951 points from the same quarter a year ago, near the top of its range since 2020.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over HUMA in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over HUMA on profitability, with a higher operating margin.
HUMA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$15M | +$9M |
| Q2 2026 | -$22.2M | +$4.8M |
| Q1 2026 | -$25.3M | +$3.6M |
| Q4 2025 | -$26.2M | +$477K |
| Q3 2025 | -$24M | -$112K |
| Q2 2025 | -$27M | -$5.5M |
| Q1 2025 | -$28.8M | -$1.1M |
| Q4 2024 | -$26.6M | -$7.4M |
HUMA has burned cash in almost every quarter: −$89M over the past year, against −$106M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over HUMA on cash generation, producing positive trailing cash flow while its opponent burns cash.
HUMA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +19% | +43.6M shares |
| 1 year | +79% | +122M shares |
| 3 years | +169% | +175M shares |
HUMA has 278M diluted shares, up 79% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over HUMA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
HUMA Net Leverage
HUMA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
HUMA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 46.2 | Neutral |
| Stochastic | 35.8 | Neutral |
HUMA's weekly RSI is 46 (neutral) and its Stochastic is 36 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
HUMA PE vs Healthcare Sector
HUMA has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
HUMA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.48 | 25% above |
| 20 week MA | $0.58 | 3.4% above |
| 50 week MA | $0.83 | 28% below |
| 100 week MA | $1.66 | 64% below |
| 200 week MA | $2.86 | 79% below |
HUMA has bounced recently, but its long-term trend is still down: it's above its 8- and 20-week averages, but 79% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over HUMA on trend strength, trading above more of its moving averages.
HUMA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.81 | $9.99 | +1.8% |
| 2021 | $9.99 | $7.76 | -22% |
| 2022 | $7.76 | $2.30 | -70% |
| 2023 | $2.30 | $2.84 | +23% |
| 2024 | $2.84 | $5.50 | +94% |
| 2025 | $5.50 | $1.07 | -81% |
| 2026 YTD | $1.07 | $0.60 | -44% |
HUMA has finished lower in three of the last six years. It's down 44% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over HUMA on returns for 2026, with the stronger performance.